Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, GlaxoSmithKline (GSK - Analyst Report) announced that the US Food and Drug Administration (FDA) has extended the review period for Glaxo’s oncology candidate, trametinib, by three months. A final decision from the FDA on the marketing application of trametinib is now expected by Sep 3, 2013.

The FDA extended the review period in order to review additional manufacturing data submitted by Glaxo recently.

Glaxo is looking to get trametinib approved for the BRAF V600 mutation-positive metastatic melanoma indication. In Aug 2012, Glaxo submitted a new drug application (NDA) to the FDA for trametinib in the above mentioned indication.

In Europe, Glaxo submitted a regulatory application for trametinib as a monotherapy and in combination with another oncology candidate, dabrafenib, for the BRAF V600 mutation-positive metastatic melanoma indication in Feb 2013. Additional manufacturing data will also be shared with the European Medicines Agency (EMA).

In a separate development, Glaxo submitted an NDA to the FDA for its chronic obstructive pulmonary disease (COPD) candidate, umeclidinium bromide (UMEC). Glaxo has submitted the marketing application for the candidate in Europe as well. The company plans to submit regulatory applications in other countries during the course of the year.

Glaxo is working hard to develop its pipeline. A number of pipeline related news is expected in the coming quarters. We are encouraged by the progress of Glaxo’s pipeline. We are also pleased with Glaxo’s efforts to control cost and restructure operations. However, we remain concerned about the challenges faced by the company in the form of generic competition.

Glaxo carries a Zacks Rank #3 (Hold) in the short run. Companies that currently look attractive include UCB (UCBJF), Athersys, Inc. (ATHX - Snapshot Report) and Catalyst Pharmaceuticals Partners Inc. (CPRX - Snapshot Report). All three stocks carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%